Adoptive cell therapy (ACT) is a kind of immunotherapy, in which T cells are genetically modified to express a chimeric antigen receptor (CAR) or T cell receptor (TCR). Adoptive cell therapy has made a great difference in treating multiple types of tumors. Some approaches of ACT involve directly isolating body’s immune cells and simply expanding their numbers, whereas other approaches involve genetically engineering body’s immune cells (via gene therapy) to enhance cancer-fighting capabilities
The global adoptive cell therapy market is estimated to be valued at US$ 4,932.5 million in 2022 and is expected to exhibit a CAGR of 21.5% during the forecast period (2022-2030).
Figure 1. Global Adoptive Cell Therapy Market Share (%) in Terms of Value, By Application, 2022
Increasing product approvals is expected to drive the market growth during the forecast period.
The increasing product approvals for adoptive cell therapy is expected to drive the global adoptive cell therapy market growth over the forecast period. For instance, in February 13, 2022, Innovent Biologics, Inc., a world-class biopharmaceutical company, together with IASO Biotherapeutics, a clinical-stage biopharmaceutical company jointly announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) had formally granted Orphan Drug Designation (ODD) to company’s co-developed fully-human B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma.
|Base Year:||2021||Market Size in 2022:||US$ 4,932.5 million|
|Historical Data for:||2017-2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||21.5%||2030 Value Projection:||US$ 23,440.7 Mn|
Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs
|Restraints & Challenges:||
Figure 2. Global Adoptive Cell Therapy Market Share (%), By Type, 2022
Rising prevalence of cancer is expected to drive the market growth during the forecast period
Rising prevalence of cancer is expected to drive the global adoptive cell therapy market growth during the forecast period. For instance, according to the data published by the National Cancer Institute stated that there were an estimated 459,058 people living with leukemia in the U.S. in 2018.
Global Adoptive Cell Therapy Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 426 million infected individuals worldwide, as of February 23, 2022.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.
Furthermore, players operating in the global adoptive cell therapy market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening diseases. The coronavirus pandemic has negatively impacted the development, production, and supply of adoptive cell therapy products
Global Adoptive Cell Therapy Market: Restraint
The major factors that is expected to hinder growth of the global adoptive cell therapy market include side effects associated with adoptive cell therapy. Common side effects associated with adoptive cell therapies may include but are not limited to acute kidney injury, bleeding episodes, heart arrhythmias, chills, constipation, cough, cytokine release syndrome (cytokine storm), decreased appetite, delirium, diarrhea, dizziness, and others.
Major players operating in the global adoptive cell therapy market include Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs.
Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. Types of adoptive cell therapy include chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor infiltrating lymphocytes (TILs), and natural killer (NK) cells. Adoptive cell therapy involve use of immune cells that are grown in the lab in large numbers followed by administering them to the body to fight cancer. Sometimes, immune cells that naturally recognize melanoma are used, while other times they are modified to make them recognize and kill the melanoma cells. Adoptive cell therapy is also called T-cell transfer therapy, and cellular immunotherapy.
Key players operating in the global adoptive cell therapy market are focusing on adoption of growth strategies such as product launch, collaboration, and fundraise which are expected to drive the market growth during the forecast period. For instance, in January 2021, Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma. Moreover, in November 2019, Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company announced that they have entered into a development, license and supply agreement. This collaboration between Zelluna Immunotherapy and Glycostem Therapeutics BV will focus on the development and manufacture of allogeneic TCR guided NK cell therapies (TCR-NK’s) for the treatment of patients with cancer
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.